One employee is dismissed, another has resigned, and three others are put on administrative leave.
GlaxoSmithKline (GSK) issued a statement to say it and the scientific publication Nature Medicine recently became aware of allegations of misrepresentation of data in a research paper written by scientists at GSK’s China research center and published in Nature Medicine in 2010 (1). The published study was from preclinical, early-stage research and did not directly involve patients, according to GSK. The article examined the role of interleukin-7 in T helper type 17 cell survival and expansion in treating autoimmune disease.
“The integrity of our research is critical to our work and when these allegations came to light, we immediately contacted the journal to tell them that we were taking the charges seriously and would be investigating thoroughly,” said GSK in the statement. “Regretfully, our investigation has established that certain data in the paper were indeed misrepresented. We’ve shared our conclusion that the paper should be retracted and are in the process of asking all of the authors to sign a statement to that effect, according to Nature Medicine’s procedure.”
GSK says that one individual has been dismissed from GSK, a second has submitted his resignation, and three others have been placed on administrative leave, pending a final review. “We are committed to the highest ethical and scientific standards and regulators, physicians, and patients can have confidence in the research we carry out.” said GSK in its statement.
Reference
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.